Adult T-cell leukemia (ATL) is a fatal neoplasm derived from CD4-positive T-lymphocytes, and regardless of intensive chemotherapy, its mean survival time is less than 1 year. Nuclear factor-jB (NF-jB) activation was reported in HTLV-I associated cells, and has been implicated in oncogenesis and resistance to anticancer agents and apoptosis. We studied the effect of a proteasome inhibitor, bortezomib (formerly known as PS-341), on ATL cells in vitro and in vivo. Bortezomib could inhibit the degradation of IjBa in ATL cells, resulting in suppression of NF-jB and induction of cell death in ATL cells in vitro. Susceptibilities to bortezomib were well correlated with NF-jB activation, suggesting that suppression of the NF-jB pathway was implicated in the cell death induced by bortezomib. Although the majority of the cell death was apoptosis, necrotic cell death was observed in the presence of a caspase inhibitor, z-VAD-fmk. When bortezomib was administered into SCID mice bearing tumors, it suppressed tumor growth in vivo, showing that bortezomib was effective against ATL cells in vivo. These studies revealed that bortezomib is highly effective against ATL cells in vitro and in vivo by induction of apoptosis, and its clinical application might improve the prognosis of patients with this fatal disease.
Introduction
Adult T-cell leukemia (ATL) has been established as a distinct clinical entity based on the clinical features and geographic distribution of patients.
1,2 Although G-CSF-supported combination chemotherapy improved the survival (mean survival time, 13 months), 3 the prognosis of aggressive ATL remains poor, with death usually occurring due to opportunistic infections or drug resistance. 4, 5 Therefore, development of anticancer drugs designed to overwhelm the resistance of ATL cells is urgently needed.
Tax is a 40-kDa protein encoded by the pX region in the human T-cell leukemia virus type (HTLV-I) genome, and is thought to play a central role in the leukemogenesis of ATL through its pleiotropic actions. 6 Tax can activate not only the transcription of viral genes but also that of a number of cellular genes through several distinct transcription factors. Tax can activate the nuclear factor-kB (NF-kB) pathway through direct interaction with IKKg. IKKa, b and g form a 700 kDa complex, in which IKKg functionally adapts Tax into the large complex. 7 The activated complex causes IkBa to be phosphorylated, ubiquitylated, and subsequently degraded by proteasomes. 8 The degradation of IkBa allows NF-kB proteins to translocate into the nucleus and bind their DNA-binding sites to activate the transcription of target genes, including cytokines, chemokines, stress-response genes, and antiapoptotic genes. On the other hand, ATL cells without Tax expression also exhibited the activated NFkB pathway, although its mechanism remains unknown. 9 Proteasome inhibitors are novel antitumor agents with preclinical evidence of activity against hematological malignancies and solid tumors. 10, 11 Among them, a boronic acid dipeptide with selective activity as a proteasome inhibitor, bortezomib, is the first proteasome inhibitor to be approved for clinical use. 10, 12 Although numerous molecular targets of proteasome inhibitors have been proposed, 13 one of the mechanisms is that inhibition of the proteasome abrogates degradation of IkBs induces their cytoplasmic accumulation, which blocks the nuclear translocation and transcriptional activity of NF-kB. This effect may account in part for the antitumor effect of bortezomib. From this point of view, suppression of the NF-kB pathway by bortezomib might be useful as a therapy against ATL.
In this study, we investigated the antitumor effects of bortezomib on HTLV-I-infected cell lines in vitro and in vivo, and primary ATL cells in vitro. The findings of this study that bortezomib exhibited antitumor activities towards ATL cells both in vitro and in vivo suggest a clinical potential for treatment of this fatal disease, ATL.
Materials and methods

Cells
In all, 10 HTLV-I associated cell lines were used in the present study: ED(À), ATL-43Tb(À), ATL-55T( þ ), TL-Om1, Sez627, ATL-35T, MT-1, MT-2, MT-4, and Hut102. 14, 15 Four HTLV-I nonassociated T-cell lines, Jurkat, Sup-T1, CEM, and Hut78, were used as controls. After informed consent, peripheral blood mononuclear cells (PBMCs) were isolated from patients with acute ATL by Ficoll-Hypaque.
Drugs
The proteasome inhibitor, bortezomib (kindly provided by Millennium Pharmaceuticals, Cambridge, MA, USA), was dissolved in DMSO and stored at À201C until use. For in vivo experiments, we used bortezomib mixed with mannitol to increase solubility. Anti-Fas mAb, CH11, and z-VAD-fmk were purchased from MBL (Nagoya, Japan), and the PEPTIDE INSTITUTE INC (Osaka, Japan).
MTT assay
The inhibitory effects of bortezomib on cell growth were assessed by measuring the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) dye absorbance of the cells.
Measurement of apoptotic cell death
For detection of apoptosis, the Annexin V-binding capacities of the treated cells were examined by flow cytometry using an Annexin V-FITC Apoptosis Detection Kit (MBL, Nagoya, Japan), according to the manufacturer's instructions. For fresh ATL cells, the percentages of specific apoptosis were calculated as follows: % specific apoptosis ¼ (Annexin V positivityÀspontaneous Annexin V positivity)/(100Àspontaneous Annexin V positivity) Â 100. To detect DNA fragmentation by the TUNEL assay, we used a MEBSTAIN Apoptosis Kit Direct (MBL) (see supplemental information).
Evaluation of NF-kB activity
The nuclear extracts were prepared as reported previously. The DNA-binding activity of NF-kB in the HTLV-I associated cell lines was quantified by enzyme-linked immunosorbent assay (ELISA) using a Trans-AMt NF-kB p65 Transcription Factor Assay Kit (Active Motif North America, Carlsbad, CA, USA), according to the manufacturer's instructions (see supplemental information).
Immunoblotting
Western blot was performed as described previously, with primary antibodies against IkBa or a-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or Tax (MI-73). 16 The membranes were washed in 0.5% TPBS, and incubated with the secondary antibody, HRP-conjugated anti-rabbit IgG or antimouse IgG (Santa Cruz Biotechnology), followed by visualization of the proteins by enhanced chemiluminescence films (Amersham Pharmacia Biotech, Buckinghamshire, UK) and a reagent (Santa Cruz Biotechnology). The intensities of the IkBa bands were quantified using ATTO densitograph 4.0 (ATTO, Tokyo, Japan).
Morphological evaluation by electron microscopy
For observation by transmission electron microscopy, ED(À) cells (4 Â 10 7 ), which were cultured with or without bortzomib, were fixed in 2% glutaraldehyde (Nacalai Tesque) in 0.1 M phosphate-buffered saline, and observed with a Hitachi H-7000 electron microscope (Hitachi, Tokyo, Japan) as reported previously. 17 
Xenograft murine model
Statistical analysis
The EC 50 s of bortezomib against the different cell lines were studied by the nonparametric Mann-Whitney U test. The differences in NF-kB activation between HTLV-I associated cell lines and nonassociated T-cell lines, and IkBa expression between Tax-expressing and nonexpressing cell lines were statistically analyzed using Welch's t-test. A P-value less than 0.05 denoted a statistically significant difference. The correlation between the EC 50 of bortezomib and NF-kB activation was analyzed by the Spearman's correlation coefficient by the rank test.
Results
Bortezomib induced cell death of HTLV-I associated cell lines
First, we investigated the in vitro effects of bortezomib on HTLV-I associated and nonassociated T-cell lines by MTT assays. Although the sensitivity to bortezomib varied among the cell lines studied, HTLV-I associated cell lines were more susceptible to bortezomib than HTLV-I nonassociated T-cell lines (Table 1 ) (P ¼ 0.024, Mann-Whitney). Two types of HTLV-I cell Table 1 Sensitivity to bortezomib in various T-cell lines 14 On the other hand, HTLV-I-infected cell lines that were established in vitro or HTLV-I cell lines derived from nonleukemic cells usually expressed Tax protein. Although Tax expression was reported to be associated with resistance against apoptosis, 18 it did not influence the susceptibility to bortezomib among the HTLV-I associated cell lines (P ¼ 0.116, MannWhitney).
Bortezomib inhibits NF-kB activation of HTLV-I associated cell lines
Constitutive activation of the NF-kB pathway was previously reported in HTLV-I associated cell lines, and has been shown to be critical for the proliferation and inhibition of apoptosis in Tax-expressing cells. 6, 7 Although Tax protein can activate NFkB by enhanced degradation of IkB, ATL cells without Tax expression also showed the activated NF-kB. 9 In order to study the NF-kB activity in HTLV-I associated cell lines, the DNAbinding activity of NF-kB was quantified by an ELISA assay as described. As shown in Figure 1a , HTLV-I associated cell lines exhibited the constitutive activation of NF-kB, which was statistically significant in HTLV-I associated cell lines compared with other T-cell lines (P ¼ 0.02, Welch's t-test). To confirm the specificity of the assay, we used two oligonucleotides provided as a competitor for NF-kB binding. Wild-type consensus oligonucleotides could prevent NF-kB binding to the probe immobilized on the plate. Conversely, the mutated consensus oligonucleotide had no effect on DNA binding (data not shown).
Previous studies have shown that Tax binds to IKKg/NEMO, resulting in enhanced degradation of IkBa, and activation of NFkB in Tax-expressing cell lines. 19,20 Therefore, we next analyzed the protein levels of IkBa and Tax. The IkBa protein was statistically more decreased in Tax-expressing cell lines than in Tax nonexpressing cell lines (P ¼ 0.027, Welch's t-test) (Figure 1b) . However, the NF-kB activations did not differ between Tax-expressing and nonexpressing HTLV-I associated cell lines (P ¼ 0.23, Welch's t-test).
Since the higher activation of NF-kB and increased susceptibility to bortezomib in HTLV-I associated cell lines suggested their association, we analyzed the correlation between NF-kB activation and susceptibility to bortezomib. Indeed, the EC 50 s of T-cell lines were inversely correlated with the activation of NFkB (rs ¼ À0.817, Spearman's correlation coefficient by rank test) (Figure 1c) . From this result, the enhanced activation of NF-kB was associated with increased susceptibility to bortezomib among the HTLV-I associated cell lines.
In order to clarify the effect of bortezomib, we analyzed the NF-kB activity and protein level of IkBa in ED(À) (Tax-negative) and MT-4 (Tax-positive) cells after treatment with bortezomib. As shown in Figure 2a , bortezomib inhibited the NF-kB activation in both ED(À) and MT-4 cells in a time-dependent manner. Consistent with the decreased activity of NF-kB, bortezomib induced the accumulation of both IkBa and the slower migrating form of phosphorylated IkBa in MT-4 cells (Figure 2b ). On the other hand, bortezomib increased only phosphorylated IkBa in ED(À) cells, suggesting that the increment of phosphorylated IkBa was associated with the inhibition of NF-kB. In addition, bortezomib did not influence the expression of Tax protein in either ED(À) or MT-4 cells, which showed that Tax was not the target of the proteasome inhibitor.
Bortezomib induced both apoptotic and nonapoptotic cell death
To study whether the cell death induced by bortezomib was apoptosis, we analyzed the bortezomib-induced cell death by the TUNEL method. Bortezomib induced apoptosis in ED(À) (60.6%) and MT-4 (77.9%) cells (supplemental Figure 1a) , indicating that most of the cell deaths induced by bortezomib was apoptosis, as has been observed in other cancers. However, the pan-caspase inhibitor, z-VAD-fmk, that inhibits caspases 1, 3, 4, 7 and 8, did not inhibit the cell death of ED(À) cells after treatment with bortezomib, whereas it suppressed the Fasmediated cell death ( Figure 3a) . As shown in Figure 3b , z-VADfmk completely blocked the apoptosis induced by bortezomib whereas cell death estimated by PI and Annexin V staining was still detected in 75.7% of cells, suggesting that the cell death induced by bortezomib in the presence of z-VAD-fmk might not be apoptotic. Moreover, z-VAD-fmk could not block the loss of Figure 1b) . To confirm that cell death was induced by bortezomib in the presence of z-VAD-fmk, the bortezomib treated cells were studied by transmission electron microscopy. Treatment of bortezomib alone caused condensation and fragmentation of the nuclei as well as shrinkage of the cells (Figure 4b ), which are characteristics of apoptosis. When the cells were treated with bortezomib in the presence of z-VADfmk, their cytoplasms appeared electron translucent accompanied by cellular swelling and their mitochondrial matrices were swollen (Figure 4c and d) , which were characteristics of necrosis. These findings indicated that although bortezomib induced apoptosis, it induced necrosis in the presence of z-VAD-fmk.
Antitumor activity of bortezomib in vivo
Since bortezomib was found to rapidly exit the plasma compartment, 10 we analyzed the in vivo effects of bortezomib on ATL cells. A previous report showed that bortezomib monotherapy was not effective in a murine ATL model although it has the ability to enhance anti-Tac activity. 21 We used ED(À) cells derived from leukemic cells in an ATL patient. As shown in Figure 5 , the treatment with bortezomib (1 mg/kg) alone significantly inhibited the growth of ED(À) cells in vivo without the obvious adverse effects. This result indicated that bortezomib monotherapy was effective against ED(À) cells in vivo.
Figure 2
Bortezomib induced the accumulation of phosphorylated IkBa and inhibited NF-kB activity. (a) ED(À) and MT-4 cells were treated with bortezomib (100 nM) for the indicated times, followed by nuclear extraction. NF-kB activities of nuclear extracts (2 mg per well) at the indicated times were quantified using a Trans-AMt NF-kB p65 Transcription Factor Assay Kit (Active Motif North America), according to the manufacturer's instructions. (b) ED(À) and MT-4 cells were treated with bortezomib (100 nM) for the indicated times, followed by protein extraction. Whole-cell extracts (30 mg per lane) of treated cells were immunoblotted with specific antibodies against IkBa, Tax, and a-tubulin. 
Discussion
Regardless of the progress in the virological, epidemiological and clinical aspects of HTLV-I and ATL, the prognosis of patients with ATL remains poor. Among the factors implicated in this poor prognosis, immunodeficiency due to impaired cellmediated immunity and drug-resistance of ATL cells are major obstacles to its treatment. 4 Constitutive NF-kB activation was demonstrated not only in HTLV-I associated cell lines but also in fresh ATL cells regardless of Tax expression, 9 which could contribute to the drug-resistance of ATL cells through over expression of antiapoptotic genes such as bcl-xL. In the present study, we have revealed that bortezomib exerted antitumor activity against HTLV-I associated cell lines (in vitro and in vivo) and fresh ATL cells (in vitro). Although several targets have been proposed for the action of bortezomib, including upregulation of p53, p21, and inhibition of NF-kB activation, 11 this study showed the correlation between susceptibility to bortezomib and NF-kB activation, suggesting that NF-kB is the major target of bortezomib in ATL cells.
Recently, caspase-independent cell death has been studied in programmed cell death. 22 When caspases were inhibited by z-VAD-fmk, Fas-mediated signaling could induce necrotic cell death instead of apoptosis. 23, 24 Apoptosis was induced in T-lymphocytes treated with NF-kB inhibitor, whereas it could cause nonapoptotic cell death in the presence of z-VAD-fmk. 25 This also suggests that bortezomib-induced cell death is similar to cell death induced by NF-kB inhibition, which strengthen the possibility that inhibition of NF-kB plays a central role in bortezomib-induced cell death. 
Figure 5
Antitumor efficacy of bortezomib against ATL-derived cell line ED(À) xenografts in SCID mice. ED(À) cells were injected subcutaneously into the right flanks (4 Â 10 7 cells/mouse) of 5-weekold female SCID mice. When the tumor size became measurable, animals were treated intraperitoneally twice a week with either vehicle or bortezomib for 10 days. Tumor volumes were determined as described in the Materials and Methods, and are presented as the average values and s.d. of six mice.
Potent effect of bortezomib on ATL cells Y Satou et al
Tax-expressing cell lines exhibited resistance to apoptosis induced by traditional anticancer drugs, in which upregulations of MDR1 and LRP have been proposed as mechanisms. 26 In addition, Tax can activate NF-kB, which would lead to upregulation of antiapoptotic gene products, such as Bcl-2, Bcl-xL and inhibitors of apoptosis proteins. These actions of Tax render HTLV-I transformed cells resistant to apoptosis induced by anti-cancer drugs or Fas-mediated signals. 18 Such resistance against apoptosis conferred by Tax might account for the poor response of ATL cells to anticancer drugs. In this regard, it is noteworthy that bortezomib was effective against both Taxexpressing and Tax nonexpressing cells, indicating that bortezomib could overcome the resistance conferred by Tax protein.
On the other hand, it is controversial whether Tax is expressed and plays a role in the proliferation of ATL cells in vivo. ATL cells frequently lose the expression of Tax by several mechanisms: loss of the 5 0 -LTR, nonsense mutations of the tax gene, and silencing by DNA methylation. 16 However, there have been several reports of the detection of Tax expression in fresh ATL cells, which might be implicated in the resistance of ATL cells. Since such ATL cells expressing Tax protein are considered to be an impediment for therapy, bortezomib should be an attractive agent against such ATL cells.
Although NF-kB activation in HTLV-I associated cell lines was inhibited by bortezomib through blockade of IkBa degradation, the changes in IkBa expression induced by bortezomib were different between Tax-expressing and Tax nonexpressing cell lines. The decreases in basal IkBa expression were demonstrated in Tax-expressing cell lines, but not in Tax nonexpressing cell lines, while both types of cell lines exhibited constitutive NF-kB activation. The common finding observed after bortezomib exposure in both types of cell lines was the accumulation of phosphorylated IkBa. It has been reported that phosphorylation of IkBa alone was not enough to release active NF-kB, but that subsequent degradation was necessary to activate NF-kB. 27 Thus, our results revealed that accumulation of phosphorylated IkBa, but not the nonphosphorylated form, could inhibit NF-kB activity, and induce apoptosis.
It has been previously reported that bortezomib was a potential therapeutic agent for ATL in combination with an anti-CD25 antibody, but that treatment with bortezomib alone was not sufficient for inhibition of tumor growth in vivo. 21 In this study, bortezomib monotherapy showed sufficient activity to suppress tumor cell growth in vivo. Although this discrepancy might be derived from differences in the treatment regimen and/ or tumor cell characters, our study suggests further potential for bortezomib against ATL cells.
In conclusion, we showed the potential effects of bortezomib on ATL in vitro and in vivo by inhibition of NF-kB activation. These results suggest that bortezomib has potential as an antitumor agent against the fatal neoplastic disease, ATL.
